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The aggregation and deposition onto neuronal cells of amyloid β-peptide (Aβ) is central to the pathogenesis of Alzheimer's disease.
Accumulating evidence suggests that membranes play a catalytic role in the aggregation of Aβ. This article summarizes the structures and
properties of Aβ in solution and the physicochemical interaction of Aβ with lipid bilayers of various compositions. Reasons for discrepancies
between results by different research groups are discussed. The importance of ganglioside clusters in the aggregation of Aβ is emphasized. Finally,
a hypothetical physicochemical cascade in the pathogenesis of the disease is proposed.
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Alzheimer's disease (AD), a progressive cognitive decline, is
the most common form of dementia. The pathological hallmarks
of AD brains are extracellular senile plaques and intracellular
neurofibrillary tangles. It is widely accepted that the amyloid
β-peptide (Aβ), which exists in fibrillar forms as a major
component of senile plaques, is central to the development of
AD [1,2]. Aβ is a peptide composed of 40–42 amino acids and
generated from proteolytic cleavage of amyloid precursor
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770 residues depending on the isoform), by β- and γ-secretases
(Fig. 1). Aβ is present at a very low concentration (<10−8 M) in
biological fluids [3], and its physiological role is unknown.
According to the so-called Aβ hypothesis, the conversion of
soluble, nontoxic Aβ to aggregated toxic Aβ rich in β-sheet
structures ignites the neurotoxic cascade(s) of Aβ [4].
Accumulating evidence suggests that the most neurotoxic
species are soluble, nonfibrillar oligomers acting as intermedi-
ates during the formation of aggregates (fibrils) [5–11], although
fibrils also exert mild toxicity including neuritic dystrophy and
synaptic abnormality [8,11–16]. Jarrett and Lansbury, Jr.
suggested that Aβ fibrillizes by the nucleation-dependent
polymerization mechanism and lipids could act as heteroge-
neous seeds for the polymerization [17]. Aβ–membrane
interactions have been extensively investigated to elucidate the
molecular mechanisms of the Aβ-induced cellular dysfunctions
underlying the pathogenesis of AD. It is naturally conceivable
that Aβ interacts with membranes because it is an enzymatic
product of the transmembrane protein APP. This review article
mainly summarizes physicochemical Aβ–membrane interac-
tions in most physiologically relevant systems, i.e. the interac-
tion of full-length Aβ-(1–40) or Aβ-(1–42) with lipid bilayers,
althoughmany studies also use fragment peptides or other model
membrane systems, such as monolayers and detergent micelles.
In particular, the importance of ganglioside clusters in the
fibrillization of Aβ is emphasized. Aβ also chemically or
biochemically interacts with lipids. For example, lipid oxidation
products chemically modify Aβ, enhancing its aggregation [18].
Conversely, Aβ oxidizes other molecules including lipids by
generating reactive oxygen species in the presence of copper or
iron [19,20]. Aβ also affects lipid metabolism [21], while lipids
regulate the production of Aβ [21–24].Fig. 1. The amino acid sequence of Aβ-(1–42) and a hypothetical model of the
aggregation of Aβ induced by ganglioside clusters. Aβ is generated, at least
partly, in lipid rafts composed of sphingolipids and cholesterol by the
enzymatic cleavage (β- and γ-secretases) of APP. Aβ is soluble, and takes an
unordered structure. Once ganglioside clusters are generated in a cholesterol-
dependent manner, Aβ binds to the clusters, forming an α-helix-rich structure
at lower peptide-to-ganglioside ratios, whereas the peptide changes its
conformation to a β-sheet at higher ratios. The β-sheet form facilitates the
aggregation (fibrillization) of Aβ, leading to cytotoxicity.2. Aβ in solution
To understand Aβ–membrane interactions, the structures and
properties of Aβ in solution should be elucidated, because
different species of Aβ would interact differently with
membranes. Aβ is amphipathic: The N-terminal 28 residues
corresponding to the extracellular part of APP is hydrophilic,
whereas the C-terminal remainder corresponding to the
membrane-spanning domain is hydrophobic (Fig. 1). The
hydrophilic part has 6 acidic amino acids (D1, E3, D7, E11,
E22, and D23) with pKa values of 4.3–4.5 in D2O, whereas the
number of basic amino acids is only 3 (R5, K16, and K28),
although there are 3 His residues with pKa values of 6.5–6.6
[25,26]. Thus, Aβ is negatively charged at physiological pH, and
electrically neutral at weakly acidic pH (∼5.5), where the
formation of Aβ fibrils is most accelerated [27].
The amphipathic Aβ is surface active, and lowers the surface
tension of water [28–30]. Above a critical concentration of
15.5–17.5 μM, Aβ-(1–40) forms micellar aggregates at pH 7.4
[29,31]. Aβ-(1–42) forms a stable trimer or tetramer at
concentrations above ∼12.5 μM [32]. At lower concentrations,
the peptide was previously reported to exist as a dimer, as
determined by gel filtration analysis using globular proteins as
molecular weight standards [28,33,34]. However, a recent study
showed that this apparent dimeric species can be regarded as a
monomer using dextrans as standards [35].
The state of Aβ in solution depends on various factors, and
this may be a reason for discrepancies between results by
different research groups. Aβ, especially Aβ-(1–42), tends to
easily self-aggregate, forming oligomers in solution [32]. This
tendency is dependent on the production lot [36] as well as the
salt form (trifluoroacetic acid or HCl) [37] of the synthetic
peptide. Contamination by trace amounts of metals such as zinc,
copper, and iron promotes self-aggregation of Aβ [38].
Commercially available Aβ may contain nontrivial amounts of
impurities [39]. Furthermore, the method by which the solution
is prepared significantly affects the state of Aβ in solution.
Dissolution into dimethylsulfoxide or hexafluoroisopropanol is
often used to obtain monomeric Aβ [40]. However, some
researchers use other solvents, such as trifluoroethanol, to make
a stock solution of Aβ. The use of organic solvents may result in
another complication. Aβ takes a random coil in aqueous
solution whereas it assumes secondary structures in organic
solvent-containing media [41,42]. The initial conformation of
Aβ in stock solution may affect subsequent peptide–lipid
interactions. One of the most reliable ways to prepare
monomeric Aβ is to dissolve Aβ in 0.02% ammonia on ice
and remove any large aggregates by ultracentrifugation [43].
The Aβ solution prepared by this method does not form fibrils
upon incubation at 37 °C for a few days.
3. Interaction of Aβ with phospholipids and cholesterol
3.1. Zwitterionic phospholipids
Phosphatidylcholine (PC) and sphingomyelin (SM) are major
zwitterionic phospholipids in mammalian cells. Most studies
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release assay [42], sucrose density gradient centrifugation [46],
fluorescence [47,48], and electrophysiological method [49] that
freshly solubilized Aβ-(1–40) [42,44–49] as well as Aβ-(1–42)
[42] (assumed to be a monomer) do not interact with PC at
neutral pH [42,44–49], although weak interaction has been also
reported using dye leakage assay [30], CD [50], and surface
plasmon resonance assay [51]. Interestingly, however, infrared
studies reported that the presence of oxidatively damaged PC
significantly accelerates the accumulation of Aβ-(1–42) [52],
which promotes amyloid formation by Aβ-(1–40) [53].
The method of preparation (the addition of Aβ to preformed
vesicles or the incorporation of the peptide during the
preparation of vesicles) also significantly affects the results
[54,55]. Aggregated Aβ-(1–40) tends to interact with PC in the
liquid-crystalline state, ordering acyl chains, as revealed by
measurements of diphenylhexatrien fluorescence anisotropy
[47,51,56]. Fluorescent analogs of PC, stearic acid, and
especially cholesterol also bind to only aggregated Aβ-(1–40)
[57]. At pH 6, there are conflicting reports that Aβ-(1–40)–PC
interaction occurs [47,51], and that it does not [42]. This
discrepancy may be related to the tendency of the peptide to
aggregate at this pH [27].
Very little information is available on Aβ–SM interaction.
Kakio et al. reported that Aβ-(1–40) with the diethylaminocou-
marin dye at the N-terminus (DAC-Aβ) did not bind to SM
liposomes even at a high lipid-to-peptide ratio (L/P) of 3000, as
judged from the lack of increase in fluorescence of DAC-Aβ
[58]. Unlabeled Aβ-(1–40) does not interact with SM either
[44]. In contrast, a considerable potentiation of fibrillation of
Aβ-(1–42) was observed in the presence of SM-containing
liposomes [59]. Neither Aβ-(1–40) nor Aβ-(1–42) induced dye
release from ceramide liposomes [46].
3.2. Acidic phospholipids
The interaction of Aβ with acidic phospholipids is again
controversial. Aβ-(1–40) [44,60] as well as DAC-Aβ [48] does
not bind to phosphatidylserine (PS) liposomes at neutral pH. In
contrast, Aβ-(1–40) was reported to form ion channels in PS-
containing planar membranes [49,61,62] and induce aggregation
of PS liposomes [63]. At a lower pH, 5.5, the peptide can order
PS/PC bilayers, as determined by ESR [60]. Regarding
phosphatidylglycerol (PG), no [44,45] or only weak [47,56]
interaction was observed at neutral pH in the presence of a
physiological concentration of salt (100–150 mM). However,
CD studies showed that at a very low ionic strength, Aβ-(1–40)
binds to PG-containing membranes, forming an α-helix or a
β-sheet (depending on the peptide-to-lipid ratio) [54,64,65], and
decreasing the gel-to-liquid-crystalline phase transition tem-
perature [66]. The binding isotherm of Aβ-(1–40) to PC/PG
(3/1) liposomes was described with a partition coefficient of
0.28 M−1 and an effective electric charge of +2 [64]. The
fibrillization of Aβ-(1–40) was also accelerated in the presence
of negatively charged phospholipids including PS, phosphatidic
acid, phosphatidylinositol (PI) and cardiolipin [67]. Under these
low ionic strength conditions, the local pH near the membranesurface is significantly lowered compared to the bulk value,
because protons are concentrated at the negatively charged
surface by electrostatic attraction. Thus, the peptide takes the
electrically neutral form that may bind to lipid bilayers. Indeed,
stronger interaction of Aβ-(1–40) and Aβ-(1–42) with PG was
reported at pH 6 than pH 7 in the presence of a physiological
concentration of salt [42]. Similar observations were reported for
PI [68]. Aβ-(1–40) forms a β-sheet structure at pH 6, but not pH
7. In contrast, Aβ-(1–42) assumes a similar conformation even at
pH 7 in the presence of PI. The attachment of phosphate groups to
PI reduced interaction with the Aβ peptides. It is also noteworthy
that the enthalpy change upon the binding of Aβ-(1–40) to
PC/PG bilayers depends on the type of buffer used [64].
3.3. Cholesterol
Accumulating evidence suggests that an elevated cholesterol
level is a risk factor of AD [69,70]. Cholesterol not only
enhances the production of amyloidogenic Aβ fragments [71–
73], but also appears to strengthen Aβ–membrane interaction.
Cholesterol enhances the interaction of Aβ with ganglioside-
containing membranes, as discussed below. The incorporation
of cholesterol into PC bilayers induces Aβ-(1–40) to form α-
helices [50] and channels [49], although no interaction was
reported between DAC-Aβ and PC/cholesterol bilayers [48].
4. Interaction of Aβ with gangliosides
4.1. AD, gangliosides, and lipid rafts
Gangliosides are sialic acid-containing glycosphingolipids
(GSL) abundant in the neuronal system. Major ganglioside
species in the human soma are GM1, GD1a, GD1b, and GT1b
(Fig. 2). In 1995, Yanagisawa and colleagues discovered a
specific form of Aβ bound to GM1 in brains exhibiting early
pathological changes of AD and suggested that the GM1-bound
form of Aβ (GM1-Aβ) may serve as a seed for the formation of
toxic amyloid aggregates/fibrils [74]. Recently, a significant
increase in GM1 was reported in Aβ-positive nerve terminals
from the AD cortex [75]. Lipid rafts (vide infra) from the frontal
cortex and the temporal cortex of AD brains were also found to
contain a higher concentration of GM1 compared to an age-
matched control [76].
Physicochemical studies using model membranes suggest
that not only the transverse distribution but also the lateral
distribution of membrane lipids is heterogeneous [77]. In the
outer monolayer, GSL, SM, and cholesterol (and PC with
saturated acyl chains) form a lipid microdomain in the liquid-
ordered phase, in which the acyl chains are highly ordered like
in the gel state, whereas the lipids are laterally mobile like in the
fluid state. Proteins important for signal transduction are
proposed to be located in this microdomain, which is dubbed
as a ‘lipid raft’, although their existence in biomembranes
remains controversial [78–80]. Biochemically, lipid rafts are
defined as detergent-insoluble fractions of biomembranes.
Accumulating evidence suggests that lipid rafts serve as a
platform for the aggregation of Aβ. The production [73,81,82]
Fig. 2. Chemical structures of major gangliosides present in neurons. Cer, ceramide; Glc, glucose; Gal, galactose; GalNAc, N-acetylgalactosamine; SA, sialic acid.
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rafts. In mature rat brains [84] and human neuroblastoma cells
[85], substantial amounts of detergent-insoluble Aβ were
detected in lipid rafts. Aβ was also found to be highly
concentrated in lipid rafts of the brain in the Tg2576 transgenic
mouse [86]. Therefore, the investigation of the interaction of
Aβ with raft lipids, especially gangliosides, is of particular
importance.
4.2. Early studies
Pioneering works were carried out by two groups after the
discovery of GM1-Aβ [74]. McLaurin and Chakrabartty
reported that Aβ-(1–40) and Aβ-(1–42) bind to GM1
micelles, forming mixed α-helix/β-sheet structures [42]. The
sialic acid is essential for this interaction. The group of
Surewicz reported that Aβ-(1–40) but not Aβ-(1–28) binds to
GM1 micelles as well as the pentasaccharide moiety of GM1
[44]. The affinity of F10W-Aβ-(1–40) for various ganglioside
micelles was determined using Trp fluorescence [87]. The
dissociation constants (Kd) for the monosialogangliosides
GM1 and GM2 were 1.4 and 3.7×10−6 M, respectively, and
were several-fold smaller than the value for the pentasacchar-
ide moiety of GM1. The Kd values were an order of
magnitude smaller for the polysialogangliosides GD1a and
GT1b than the monosialogangliosides. Generally, detergents
other than gangliosides, such as SDS, also interact with Aβ,
changing the peptide's conformation and facilitating the
formation of amyloids [88–91].
Conflicting results were reported for the binding of Aβ-(1–
40) to GM1 embedded in the matrix of phospholipids.
McLaurin et al. [46] and our group [45] observed using CD
that Aβ-(1–40) did not associate with GM1 in egg yolk PC
vesicles until the GM1 content exceeded 30%. On the other
hand, F10W-Aβ-(1–40) was reported to bind to palmitoylo-
leoyl PC vesicles containing 3 mol% GM1 added to preformed
vesicles [87]. Binding studies using surface plasmon resonancealso showed that gangliosides incorporated in PC interact with
Aβ. The Kd values of Aβ-(1–42) for GM1 (20 w/w%), GD1a,
and GT1b in dimyristoyl PC were 5.2×10−7, 1.2×10−6, and
7.7×10−7 M, respectively [92]. Ariga et al. also reported [93]
that the Kd values of Aβ-(1–38), Aβ-(1–40), and Aβ-(1–42)
for GM1 in dipalmitoyl PC were 2.8×10−6, 2.1×10−6, and
1.1×10−6 M, respectively, and that the strength of binding for
various gangliosides was in the order GQ1bα>GT1aα>
GQ1b>GT1b>GD3>GD1a=GD1b>LM1>GM1>GM2=
GM3>GM4. Gangliosides incorporated into PC bilayers
facilitate the formation of Aβ-(1–40) [87] and Aβ-(1–42)
fibrils [46]. On the contrary, Chauhan et al. reported that
gangliosides had no effect on the fibrillization of Aβ-(1–40)
[67].
4.3. Importance of ganglioside cluster
Early studies did not pay attention to the ‘environments’
surrounding gangliosides. We noticed that Aβ-(1–40)–GM1
interaction was facilitated in a SM/cholesterol mixture com-
pared to a PC matrix [45]. To reveal the underlying mechanism,
we systematically investigated the interaction of Aβ-(1–40)
with various raft-like membranes using fluorescent DAC-Aβ
[48]. DAC-Aβ is useful for fluorometrically monitoring
peptide–lipid interactions, because a significant blue shift and
an enhancement in intensity are induced by a change in polarity
upon membrane-binding. The binding isotherms of DAC-Aβ to
raft-like membranes having various GM1/cholesterol/SM ratios
were determined at 30 °C. The binding constant was
independent of lipid composition (2–3×106 M−1) whereas
the binding capacity (maximal number of binding site) was
highly dependent on lipid composition (Table 1). An increase in
GM1 content from 20% to 40% cooperatively increased the
binding capacity. Cholesterol also facilitated the formation of
binding sites. We hypothesized that a cluster of GM1, which is
formed in a cholesterol-dependent manner, constituted the
binding site. To prove this hypothesis, we estimated GM1
Table 1
Binding parameters of DAC-Aβ and cluster formation of GM1 at 30 °C [48]
Lipid composition Binding constant
(106×M−1)
Binding capacity a IE/IM
b
GM1/SM/Chol
(40:30:30)
2.4±0.1 0.057±0.001 0.76
GM1/SM/Chol
(20:40:40)
2.9±0.4 0.019±0.001 0.43
GM1/SM/Chol
(20:64:16)
3.0±2.9 0.001±0.000 0.34
GM1/PC (10:90) no binding 0.24
a Bound DAC-Aβ/exofacial GM1 (mol/mol).
b Excimer-to-monomer intensity ratio. Twenty-five mol% of total GM1 was
replaced by BODIPY-GM1.
Fig. 4. A hypothetical physicochemical cascade involved in the pathogenesis of
AD.
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labeled GM1, which is facilitated by the local concentration of
the probe. The order for the formation of the excimer was in
accordance with the order of the binding capacity (Table 1).
4.4. Aggregation of Aβ in ganglioside clusters
In buffer, Aβ-(1–40) takes an unordered structure. However,
upon binding to raft-like membranes containing ganglioside
clusters, drastic conformational changes occur depending on the
peptide-to-ganglioside ratio [48,58]. Aβ assumes an α-helix-
rich structure at lower ratios (≤0.025), whereas the peptide
changed its conformation to a β-sheet at higher ratios (≥0.05).
NMR spectroscopy revealed that both Aβ-(1–40) and Aβ-(1–
42) form helix–loop–helix structures also in SDS micelles
[89,90]. Aβ-(1–40) bound to a ganglioside cluster was found to
act as a seed for the formation of fibrils (Fig. 3A) [58,94,95].
Our cell study also supports this in vitro finding. A fluorescein-
labeled Aβ-(1–40) was in the vicinity of GM1-rich domains of
plasma membranes of PC12 cells, leading to cytotoxicity [96].
Native Aβ-(1–42) also forms amyloid fibrils in the vicinity of
the domains (Fig. 3B–D, unpublished work). Furthermore, a
neurotoxic species of Aβ is also generated during the
aggregation process on liposomes containing GM1 clusters
[94]. The structure of Aβ fibrils formed via ganglioside clusters
is suggested to be different from that formed in aqueous
solution. The amide I spectrum of the former showed, in
addition to a major peak around 1630 cm−1 characteristic of a
β-sheet, a weak peak at 1695 cm−1 whereas that of the latterFig. 3. Formation of Aβ fibrils on GM1-containing liposomes and cell membranes. (A
of GM1/cholesterol/SM (4:3:3) liposomes [95]. The bar represents 200 nm. (B–D, un
37 °C. The distribution of gangliosides was detected by using the cholera toxin B sub
amyloid-specific dye Congo red (C). (D) The merging of (B) and (C) shows that amyshowed a peak around 1660 cm−1 [97]. Nordihydroguaiaretic
acid effectively disrupts the latter but not the former [95]. Tycko
and co-workers proposed a structural model using solid-state
NMR of Aβ-(1–40) fibrils formed from solution [98].
Approximately the first 10 residues are structurally disordered;
residues 12–24 and 30–40 adopt β-strand conformations and
form parallel β-sheets; residues 25–29 contain a bend of the
backbone that brings the two β-sheets in contact.
Based on the above observations, we propose a novel model
for Aβ–membrane interaction (Fig. 1). Aβ specifically binds to
a ganglioside cluster, the formation of which is facilitated by
cholesterol. Aβ undergoes a conformational transition from an
α-helix-rich structure to a β-sheet-rich one with increasing
peptide density on the membrane. The β-sheet form serves as a
seed for the formation of amyloid fibrils. The aggregation
process exerts toxicity against neuronal cells. Small com-
pounds, such as nordihydroguaiaretic acid and rifampicin, can
inhibit the membrane-mediated aggregation of Aβ [95].
This model agrees well with various previous in vitro and
in vivo observations. A link between cholesterol, Aβ, and AD
has been reported [22,23]. Diet-induced hypercholesterolemia
accelerates the amyloid pathology in a transgenic mouse
model [99]. The amount of cholesterol in the exofacial
leaflets of the synaptic plasma membrane increases in aged
[100] as well as apolipoprotein E4-knock-in [101] mice. Both
the aging and the apolipoprotein E4 allele are strong risk) Transmission electron micrograph of Aβ-(1–40) fibrils formed in the presence
published work) Aβ-(1–42) (10 μM) was incubated with PC12 cells for 24 h at
unit conjugated with Alexa Fluor 647 dye (B). Amyloids were visualized by the
loids were formed in the vicinity of ganglioside-rich domains of cell membranes.
1940 K. Matsuzaki / Biochimica et Biophysica Acta 1768 (2007) 1935–1942factors for developing AD [102]. Reductions in cholesterol
and sialic acid contents protect cells from the toxic effects of
Aβ [103], although opposite results were reported on the
effects of cholesterol on the toxicity of Aβ [104–106].
Differences in experimental conditions, such as the methods
used to change cholesterol level and cytotoxicity assays, may
affect the results.
5. Concluding remarks
It is widely accepted that the aggregation of Aβ is central to
the pathogenesis of AD. Although soluble factors, such as
clusterin (Apo J) [5] and Zn2+ ions [38], are known to facilitate
the aggregation of Aβ, membranes also play an important role.
Notably, the interaction of Aβ with ganglioside clusters is
stronger under physiological conditions, therefore physiologi-
cally important. In addition to other biochemical cascades, a
complex physicochemical cascade (Fig. 4) may be also
involved in the process of Aβ aggregation. Inhibition of one
of these steps would be a promising strategy for AD therapy.
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